SGLT2 inhibitors in T2D and associated comorbidities — differentiating within the class

SGLT2 inhibitors in T2D and associated comorbidities — differentiating within the class

Abstract Background For patients with type 2 diabetes (T2D), cardiovascular disease (CVD) is the single most common cause of mortality. In 2008 and 2012, the Federal Drug Administration (FDA) and the European Medicines Agency (EMA) respectively mandated cardiovascular outcomes trials (CVOTs) on all...

Full description

Bibliographic Details
Main Authors: Guntram Schernthaner, Heinz Drexel, Evgeny Moshkovich, Birute Zilaitiene, Emil Martinka, Leszek Czupryniak, Tamás Várkonyi, Andrej Janež, Kristine Ducena, Katarina Lalić, Tsvetalina Tankova, Martin Prázný, Lea Smirčić Duvnjak, Olga Sukhareva, Harald Sourij
Format: Article
Language:English
Published: BMC 2019-06-01
Series:BMC Endocrine Disorders
Subjects:
Type 2 diabetes
SGLT2 inhibitor
Empagliflozin
Canagliflozin
Dapagliflozin
Cardiovascular disease
Online Access:http://link.springer.com/article/10.1186/s12902-019-0387-y

Internet

http://link.springer.com/article/10.1186/s12902-019-0387-y

Similar Items